A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Aegerion Pharmaceuticals Inc (NASDAQ: AEGR) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on November 17, 2017 and NASDAQ: AEGR investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 11/17/2017 -- A deadline is coming up on November 17, 2017 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Aegerion Pharmaceuticals Inc (NASDAQ: AEGR) between April 30, 2013 and May 11, 2016.
Investors who purchased a significant amount of shares of Aegerion Pharmaceuticals Inc (NASDAQ: AEGR) between April 30, 2013 and May 11, 2016, have certain options and should contact the Shareholders Foundation by email at email@example.com or call 858-779-1554.
The settlement proof of claim form or detailed settlement notice for the settlement in the Aegerion Pharmaceuticals Inc (NASDAQ: AEGR) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/aegerion-pharmaceuticals-inc-nasdaq-aegr-investor-securities-class-action-lawsuit-01152014
In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is November 17, 2017. The class action administrator for this case is Gilardi & Co LLC.
The lawsuit was originally filed in the U.S. District Court for the District of Massachusetts against Aegerion Pharmaceuticals Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between March 15, 2012 and January 9, 2014.
According to the complaint the plaintiff alleges on behalf of a all persons or entities who purchased or otherwise acquired securities of Aegerion Pharmaceuticals Inc (NASDAQ: AEGR) between March 15, 2012 and January 9, 2014, that Aegerion Pharmaceuticals Inc and certain of its officers and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Aegerion Pharmaceuticals Inc's products include JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia.
More specifically, the plaintiff claims that the defendants made allegedly false and/or misleading statements and/or failed to disclose to Aegerion Pharmaceuticals Inc investors that Aegerion Pharmaceuticals Inc marketed its drugs in violation of the FDCA, that as a result, Aegerion Pharmaceuticals Inc faced heightened regulatory scrutiny by the FDA and other governmental bodies, and that as a result of the foregoing, Aegerion Pharmaceuticals Inc's statements were allegedly materially false and misleading at all relevant times.
Those who purchased shares of Aegerion Pharmaceuticals Inc (NASDAQ: AEGR) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels